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A  b  s  t  r  a  c  t
Objective.  – Making  a differential  diagnosis  of  psoriatic  arthritis  (PsA)  is  not  straightforward.  This is partly
because  of  its  heterogeneous  presentation  and  partly  because  many  patients  with  PsA are  initially  diag-
nosed  with psoriasis  and  treated  in  primary  care  or by  dermatologists,  with  referral  to  rheumatologists
being  delayed.  Once  diagnosed,  optimal  disease  control  requires  frequent  specialist  monitoring,  adjust-
ment  or  switching  of  therapies,  and  management  of comorbidities  and  concomitant  diseases,  as  well  as
attention to patients’  overall  well-being.  Given  the  breadth  of  expertise  that  diagnosis  and  management
of  PsA  requires,  we  sought  to define  a collaborative,  structured  framework  that  supports  the  optimisation
of  multidisciplinary  care  for patients  with  PsA  in  Europe.
Methods.  – An  expert  panel  comprising  four  rheumatologists,  three  dermatologists,  two  specialist  nurses
and one  psychologist–from  Spain,  the  United  Kingdom,  The  Netherlands,  Germany,  France  and  Italy–met
face-to-face  to  take  part  in a modified  Delphi  exercise.
Results. – The  result  of this  exercise  is  a set of  recommendations  that  are  based  on combining  published
evidence  with  the panel’s  extensive  clinical  experience.  Recommendations  can  be  implemented  in a
number  of  ways,  but the  central  call-to-action  of this  framework  is  the  need  for  improved  collaboration
between  dermatologists  (or primary  care  physicians)  and  rheumatologists.  This  could  occur  in a  variety
of different  formats:  standard  referral  pathways,  multidisciplinary  physician  meetings  to  discuss  patient
cases,  or  ‘one  stop’,  combined  clinics.
Conclusion.  – We  anticipate  that  when  the  majority  of  patients  with  PsA  receive  regular  multidiscipli-
nary  care,  improved  patient  outcomes  will follow,  although  robust  research  is  needed  to  explore  this
assumption.
© 2021  Les  Auteurs.  Publié  par  Elsevier  Masson  SAS  au nom  de  Société  franç aise  de  rhumatologie.  Cet
article est  publié  en  Open  Access  sous  licence  CC BY-NC-ND  (http://creativecommons.org/licenses/by-∗ Corresponding author at: Service de Rhumatologie, Hôpital Lariboisiere Centre
Viggo Petersen, Université de Paris, 2, Rue Ambroise-Pare, 75010 Paris, France.
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. Introduction
Psoriatic arthritis (PsA) and psoriasis (PsO) share some patho-
enic mechanisms, with PsA occurring in up to 30% of people with
sO [1,2]. However, PsA often goes undetected: in one study of
00 patients with PsO in a routine care setting, 29% were found
o have undiagnosed PsA when examined by a rheumatologist [3].
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The majority of patients with PsA present with PsO before PsA is
diagnosed, although up to 20% of patients present with PsA first,
and < 10% experience concurrent skin and joint symptoms [2,4].
Importantly, although the skin symptoms associated with PsO are
generally reversible, the joint damage associated with PsA is often
irreversible, making early diagnosis and effective treatment crucial
[5].
Challenges associated with the clinical management of PsA
have been summarised recently.[6] Among these is the heteroge-
neous presentation of PsA, which can include arthritis, spondylitis,
enthesitis, dactylitis, skin and nail involvement.[7] Making a dif-
ferential diagnosis of PsA is not straightforward. Once diagnosed,
disease control requires frequent specialist monitoring, individual
adjustment or switching of therapies, and careful management
of extra-musculoskeletal manifestations and comorbidities [8,9].
In addition, consideration of other risk factors, such as weight,
smoking and physical activity, [10,11] and of the patient’s overall
well-being, is warranted.
In the US, a multidisciplinary approach to the diagnosis and
management of PsA and PsO has recently been facilitated through
the introduction of the Psoriasis & Psoriatic Arthritis Clinics Mul-
ticenter Advancement Network (PPACMAN) – a global network of
combined dermatology and rheumatology clinics, currently inclu-
ding more than 20 clinics in the USA that provide combined care
[12]. Several different models for combined care exist globally. For
example, in North America both at the Center for Skin and Rela-
ted Musculoskeletal Diseases (SARM) at Brigham and Women’s
Hospital in Boston, MA,  [13] and at the Dermatology and Rheu-
matology Treatment (DART) Clinic in Canada, dermatologists and
rheumatologists provide concomitant care at the point of service
[14]. In Spain, there is the Psoriasis Rheumatology and Derma-
tology (PSORD) unit in the Hospital Universitario Parc Tauli in
Barcelona, where rheumatologists and dermatologists receive trai-
ning sessions on the signs and symptoms of PsA and PsO from
the perspectives of each group, and patients are then provided
with concomitant care [15]. In the Hospital Can Misses in Ibiza,
patients with psoriatic disease are referred for diagnostic pro-
blems, therapy-related issues, comorbidity management, or safety
concerns to a multidisciplinary care unit [16]. In both Spanish
clinics, patients return to their specialist for management after
diagnosis and treatment are established [Baum 2018].
Given the challenges faced with the clinical management of
PsA, there is an emerging recognition in the field that a colla-
borative, structured management of PsA by rheumatologists and
dermatologists is needed. However, the involvement of other spe-
cialists, including psychologists, gastroenterologists, primary care
physicians and specialist nurses should be considered given the
multifaceted nature of PsA. Only in this way can we facilitate effec-
tive, patient-centred care in PsA, starting from the diagnosis of PsO
or PsA – whichever comes first – and involving the patient as much
as possible throughout [17].
An expert panel was convened with the objective of developing
a collaborative framework for the multidisciplinary care of PsA in
order to address some of the challenges currently facing health-
care professionals treating patients with PsA. A unique aspect of
this expert panel was that it comprised experts from six European
countries, in order to provide regional guidance that could then be
adapted as needed and applied at a local level. The panel sought
to develop minimum standards for effective collaboration in the
management of PsA, to support the following aims:• raise awareness of PsA among a range of specialists involved in
patient care;
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provide a framework that allows for multidisciplinary care, with
patients themselves actively involved in the management of their
disease.
. Methods
An expert panel were selected on the basis of their clinical role
nd extensive experience in managing patients with PsA. The panel
omprised four rheumatologists, three dermatologists, two spe-
ialist nurses and one psychologist, from six European countries
Spain, the United Kingdom, The Netherlands, Germany, France and
taly), who  met  face-to-face to take part in a modified Delphi exer-
ise [18]. During this process, the panel identified the key area of
linical focus – multidisciplinary care in PsA – and topics therein
here a gap in current clinical management had been identified.
A literature review was carried out for relevant studies and
rticles published in English between 1 January 2009 and 31January
019, based on topics and search terms agreed by the expert panel.
atabases included PubMed/Medline, EMBASE and The Cochrane
ibrary. Supplementary manual searches were performed as nee-
ed to ensure that recent publications and relevant articles from
eference lists were included. Papers were screened for relevance
nd drawn into narrative text, which was then used to support the
rafting of the initial Delphi statements. Of 1675 articles screened,
4 were analysed and 32 were referenced during the initial draft of
vidence-based statements.
A face-to-face meeting was  held on 9 April 2019 to review the
tatements and supporting evidence. The draft recommendations
ere discussed in relation to the clinical experience of the expert
anel, who  each scored their level of agreement with each state-
ent on a scale of 1 (lowest, totally disagree) to 9 (highest, fully
gree). We  adopted a minimum requirement of ≥ 75% of the experts
coring their agreement as 7–9. If this requirement was  not met,
he statement wording was refined and scored again, in line with
 modified Delphi process. Statements were prioritised and sor-
ed according to three categories – diagnosis, management and
ducation. External validation of the revised statements was then
btained via an anonymous survey, sent by email, of another group
f clinicians who  were selected because of their relevant exper-
ise, comprising seven rheumatologists, four dermatologists, one
eneral practitioner and three nurses, representing the same coun-
ries as the expert panel. The final 12 recommendations (Table 1),
long with supporting evidence and key points of discussion, are
resented in this paper.
. Results
.1. Agreed statements
.1.1. A delay in the diagnosis of PsA is a significant contributor to
oor patient outcomes
The ACR/National Psoriasis Foundation guidelines state that
arly identification of PsA and early initiation of therapy are impor-
ant for improving long-term outcomes [19]. Despite this, in a
urvey of patients with PsO in North America and Europe, the ave-
age time from onset of joint symptoms to diagnosis of PsA was
eported to be 5 years (n = 712) [4]. In a smaller retrospective study
ased on medical records, median time from symptom onset to
atients’ first rheumatological assessment was 1 year (interquar-
ile range: 0.5–2.0; n = 283). In the same study, a 6-month delay in
iagnosis and treatment was associated with an increased risk of
eripheral joint erosion and worse patient-reported outcomes [20].
n another retrospective study of 267 patients who had PsA for ≥ 10
ears, a delay of ≥ 1 year between symptom onset and diagnosis
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Table  1
Summary of recommendations.







1. A delay in the diagnosis of PsA is a significant contributor to poor patient outcomes 9.0 (8.0–9.0) 8.0 (8.0–9.0)
2.  Limited awareness, lack of screening and delayed referrals all impact early PsA diagnosis and
treatment access
9.0 (8.75–9.0) 8.0 (7.0–9.0)
Management
3.  All patients with PsA should be screened for psychological distress and provided with appropriate
intervention as needed
8.0 (8.0–9.0) 7.0 (5.0–8.0)
4.  Management of PsA should address all aspects of the disease: skin; nail; musculoskeletal disease
symptoms (peripheral and axial); associated diseases; well-being; and QoL
9.0 (8.0–9.0) 8.0 (8.0–9.0)
5.  Management of PsA should be tailored to the severity and phenotype of disease (both skin and
musculoskeletal aspects) in each individual patient
9.0 (8.75–9.0) 8.0 (8.0–9.0)
6.  Regular objective clinical assessment of disease activity conducted by a physician or a specialist
nurse is the gold standard of care
8.0 (7.75–8.25) 8.0 (8.0–9.0)
7.  The primary treatment goal should be remission or minimal disease activity with regular
monitoring, because it is associated with better outcomes
8.5 (8.0–9.0) 8.0 (8.0–9.0)
8.  Patient–clinician consultations must address comorbidities to ensure optimal care and outcomes 9.0 (8.0–9.0) 8.0 (8.0–9.0)
9.  Multidisciplinary management could be more effective and satisfactory for patients than a
consultation with a single specialist
8.0 (7.75–9.0) 8.0 (7.0–9.0)
10.  Multidisciplinary care for patients with PsA should involve rheumatologists and dermatologists
at  a minimum, and those specialists necessary for appropriate management of the patient
9.0 (7.75–9.0) 8.0 (7.0–9.0)
Education
11.  Dermatologists should be able to identify possible signs and symptoms of PsA among their
patients with PsO, with diagnosis to be confirmed by a rheumatologist
































12.  High-quality patient–clinician education and patient understanding is key to
PsA, psoriatic arthritis; QoL, quality of life.
was a significant predictor of worse physical functioning later in
the course of the disease [21].
Once diagnosed, the time required for patients to receive effec-
tive treatment, and how this is achieved in clinical practice, is also
a key consideration. The TICOPA study in 206 patients with early,
DMARD-naïve PsA showed that treating to target based on a tight
control strategy significantly improved joint and skin outcomes
compared with standard care. Patients’ chance of reaching ACR20 at
48 weeks (primary endpoint) was higher with tight control versus
standard care (odds ratio: 1.91; 95% confidence interval: 1.03–3.55;
P = 0.0392). Patient-reported outcomes (the Bath Ankylosing Spon-
dylitis Disease Activity Index and the corresponding Functional
Index; a PsA-specific quality of life instrument, PsAQoL; and the
Health Assessment Questionnaire) also improved [22].
3.1.2. Limited awareness, lack of screening and delayed referrals
all impact early PsA diagnosis and treatment access
In the Multinational Assessment of Psoriasis and Psoriatic
Arthritis survey of 391 dermatologists and 390 rheumatologists
based in North America and Europe, > 75% stated that PsA is pro-
bably underdiagnosed due to a failure to connect skin and joint
symptoms [23]. This problem is compounded by screening tools
that are not sensitive or specific enough, nor used consistently
enough to merit regular use during time-limited consultations [6].
Improved collaboration between dermatologists, primary care
physicians and rheumatologists may  hold the key to reducing time
to PsA diagnosis, whether this takes the form of standard referral
pathways, multidisciplinary team meetings, or ‘one stop’, rapid-
access combined clinics in which the patient is seen by multiple
specialists at the same time. In addition, there is a need for further
education and training on PsA and its symptoms in specialist der-
matology clinics and in primary care, where physicians lack specific
musculoskeletal expertise and patients with PsO are not regularly
screened for PsA. An alternative to screening tools is to systemati-
cally ask patients with PsO about joint and back symptoms [24]. The
value of sensitive screening methods such as high-field magnetic
resonance imaging or ultrasound to detect subclinical joint inflam-






ring adherence 8.5 (8.0–9.0) 8.0 (8.0–9.0)
owever, studies suggest that this approach would help identify
atients at high risk of developing PsA when considered in tandem
ith other clinical symptoms such as arthralgia [25,26].
In countries such as the UK, in which many patients with mild
sO are treated in primary care [27] but without regular scheduled
ollow-ups in primary care or with a dermatologist, education of
atients themselves on the risk of PsA, its symptoms and the need
or screening is also important [28]. In particular, patients should
e made aware of the fact that symptoms associated with their
oints may  be linked to their PsO, and should be reported so that
reatment can be adjusted if needed.
.1.3. All patients with PsA should be screened for psychological
istress and provided with appropriate intervention as needed
Patients with PsA have worse QoL, not only compared with
he general population, but also compared with patients with PsO
29,30]. The numerous and varied symptoms associated with PsA
re likely to contribute to this effect on QoL [31]. However, this
oes not account for the entire psychological burden experienced
y patients: in one study, anxiety was  independently associated
ith QoL in patients with PsA, highlighting the need to specifically
ddress the psychological aspect of the disease as part of routine
atient care [32]. Another study showed that the relationship bet-
een pain and depressive symptoms in PsA is bi-directional [33].
 recently published meta-analysis (n = 31,227) highlighted that
nxiety and depression are common among patients with PsA, with
ne in three people experiencing at least mild levels of anxiety and
ne in five reporting at least mild symptoms of depression [34].
nother study based on medical records has linked major depres-
ive disorder with a significantly higher risk of developing PsA in
atients with PsO [35]. Finally, the effect of PsO or PsA treatment
tself on depression and anxiety should be considered, even if it has
ot yet been studied comprehensively.
Given the above considerations, screening for and treatment of
he psychological and physical aspects of PsA should ideally be
anaged using a co-ordinated, multidisciplinary approach. This
hould include a psychologist who can assess the patient regu-
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associated with self-managing a long-term disease that has a signi-
ficant pain component [31]. High-quality studies of the effect of
treatment on patients’ psychological well-being should also be
conducted, as a lack of agreement in published research is pre-
venting guideline development. For example, one study, indicated
that biologic treatment was associated with a lower incidence of
depression than conventional treatment in a subgroup of 7490
patients from the Psoriasis Longitudinal Assessment and Registry
[36]. However, some clinical data for apremilast and brodalumab
suggest that these treatments may  be associated with a potential
worsening of patients’ psychological well-being; overall, data on
these agents remain inconclusive in this regard [37,38].
It should be noted that this third statement, ‘all patients with PsA
should be screened for psychological distress and provided with
appropriate intervention as needed’, was agreed on during the face-
to-face meeting but was not validated externally. It is included for
readers to consider, given that caveat. Although the expert group
recognised the need for specialist assessment and intervention, the
group also recognised that resources available in different health-
care services may  limit the implementation of this statement.
3.1.4. Comprehensive management of PsA should address all
aspects of the disease: skin; nail; musculoskeletal disease
symptoms (peripheral and axial); associated diseases; well-being;
and QoL
A major challenge of treatment is the degree to which treat-
ment strategies need to be individualised to reflect the main areas
of disease activity for each patient. Consideration of the most pro-
minent symptoms (e.g. skin or joint), and identification of other
associated diseases (e.g. inflammatory bowel disease, uveitis) is the
key to selecting the most appropriate medication. Some treatments
are approved and available for multiple linked diseases.
Currently, management of PsA often begins with the isolated
treatment of either joint or skin symptoms. For skin symptoms,
a stepwise treatment approach is common, starting with topical
therapies or phototherapy. Treatment of joint symptoms typically
begins with use of non-steroidal anti-inflammatory drugs or intra-
articular steroid injections. Subsequently, patients are moved onto
systemic treatment, commonly starting with conventional synthe-
tic DMARDs, such as methotrexate, sulfasalazine and leflunomide,
followed by biologics and targeted synthetic DMARDs.[7,39] TNF
inhibitors, the first biologics to be approved in PsA, are now widely
used, as are biologic drugs targeting IL-17, IL-12/23, and CD80/CD86
and targeted synthetic DMARDs targeting phosphodiesterase type
4 inhibitor and janus kinase 1,3.[7,19,39].
Non-pharmacological interventions may  also be required to
improve patients’ QoL. This may  include psychological support,
advice on nutrition and weight loss — if appropriate — and exercise,
plus evidence-based approaches to lifestyle behaviour change.
3.1.5. Management of PsA should be tailored to the severity and
phenotype of disease (both skin and musculoskeletal aspects) in
each individual patient
Data from real-world clinical practice (n = 138) suggest that a
‘treat-to-target’ approach is also feasible outside of a trial set-
ting. This intensive treatment strategy was more likely to be
implemented in patients with high disease activity, severe skin
involvement or accompanying comorbidities at baseline [40]. A
flexible approach such as this one may  be required in practice, with
strategies being adapted according to assessment of disease activity
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.1.6. Regular objective clinical assessment of disease activity
onducted by a physician or a specialist nurse is the gold standard
f care
Patient self-reporting of joint disease activity in PsA has been
hown to correlate poorly with joint examination by a physician
41]. For this reason, monitoring of disease activity in PsA should
nclude patients’ reporting of how symptoms are affecting their
veryday lives, and also regular physical examination by an expert
ealthcare practitioner. This is highlighted in the GRAPPA and
ULAR treatment recommendations [7,39].
.1.7. The primary treatment goal should be remission or
inimal disease activity with regular monitoring, because it is
ssociated with better outcomes
Minimal disease activity has been well defined and used in cli-
ical trials [42]. GRAPPA and EULAR treatment recommendations
pecify that the aim of treatment in patients with PsA should be
emission, or, if this is not achievable, low/minimal disease acti-
ity [39]. A recent paper goes further, recommending the stringent
doption of ‘very low disease activity’ as the goal for treating-to-
arget in PsA. This measure does not permit residual disease activity
o be ‘hidden’ within some domains of composite scores, and
nsures that significant active arthritis, enthesitis, nail or plaque
sO is not present [43].
However, although it is widely acknowledged that a ‘treat-to-
arget’ strategy is effective and should cover both skin and joint
anifestations, this is rarely implemented in everyday clinical
ractice, and few data from this setting are available to support
he value of this approach. Achieving ‘treat-to-target’ goals requires
egular monitoring of disease activity, adjusting therapy and dosing
n an individual basis as needed [39].
A consideration for clinical management highlighted by the
ICOPA study is that patients who  received a treat-to-target
pproach (4-weekly review with escalation of therapy if criteria
ot met) in the tight control arm experienced a higher incidence of
erious AEs (14% vs 6% in the standard care arm). The rate of AEs was
lso higher in the tight control arm (97%) than in the standard care
rm (77%), although the proportion of AEs suspected to be related
o study drug was  similar in both arms [22]. According to interpre-
ation, these findings reinforce the need to adjust treatment plans
o the disease phenotype and to the overall health of the patient in
he everyday management of PsA.
.1.8. Patient–clinician consultations must address comorbidities
o ensure optimal care and outcomes
Major comorbidities in PsA include obesity, metabolic syn-
rome, cardiovascular disease, diabetes, liver disease, gout,
epression and anxiety [7,39]. PsA is also significantly associa-
ed with subclinical atherosclerosis and endothelial dysfunction,
nd consequently patients have an increased risk of cardiovascular
vents [44]. One study in a routine care setting (n = 2254) showed
hat cardiovascular risk factors such as hypertension and dyslipi-
aemia remain undetected or undertreated in many patients with
sA [45]. Similarly, a high proportion of patients with PsA have
etabolic syndrome (44% in one study of 283 patients). Along with
nsulin resistance, this is associated with the severity of under-
ying PsA, highlighting the need for regular monitoring of metabolic
arkers as well [46].
As outlined in the GRAPPA and EULAR treatment recommenda-
ions for PsA, comorbidities of PsA should be assessed and are part
f disease management, as well as skin and joint manifestations
f the disease. This can be done by physicians or specialist nurses:
he EULAR recommendations for the role of the nurse in the mana-
ement of chronic inflammatory arthritis recognise the extended
ole of rheumatology nurses in many countries, and that this may
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In a meta-analysis including 19,372 patients with immune-
mediated inflammatory diseases, patients with obesity and PsO
and/or PsA (n = 11,873) had 57% higher odds of failing anti-TNF
therapy than those with a body mass index not indicative of obe-
sity [48]. Weight loss is therefore an important part of disease
management for some patients. Weight loss has been reported to
significantly improve disease activity in PsA within 6 months in
one prospective cohort study (n = 46) [49]. In another cohort study,
gastric bypass surgery was shown to significantly reduce the risk
of PsA in patients with PsO (n = 12,364) [50].
Management of PsA alongside comorbidities can be complex:
potential side effects of polypharmacy need to be balanced against
the clinical benefits, especially when considering addition of treat-
ments, switching or dose alterations [51,52].
3.1.9. Multidisciplinary management could be more effective and
satisfactory for patients than a consultation with a single specialist
The central tenet of this recommendation is clinical collabora-
tion between dermatologists and rheumatologists to diagnose and
manage patients with PsA. This could be achieved by means of a
preferred referral system, in which each dermatologist has a refer-
ral ‘partner’ in rheumatology and vice versa; by multidisciplinary
outpatient clinics; or by multidisciplinary board meetings. More
specific, practical points to consider when establishing specialised
units have been considered and published elsewhere [53].
Although scarce, available evidence presented in a recent meta-
analysis indicates that management of PsO and PsA in a joint
dermatology/rheumatology consultation is effective and associated
with a greater level of patient satisfaction [54].
Another option to consider is that follow-up of patients with
PsA (and other chronic inflammatory arthritides) can be achieved
using a combination of clinics led either by rheumatologists or
by specialist nurses. One study in patients undergoing biological
treatment showed that replacing one of two annual rheumatolo-
gist visits with a nurse-led consultation provided the same level of
clinical outcome compared with two rheumatologist visits [55,56].
3.1.10. Multidisciplinary care for patients with PsA should involve
rheumatologists and dermatologists at a minimum, and those
specialists necessary for appropriate management of the patient
Although dermatologists and rheumatologists should lead the
collaborative care process in PsA, assistance of both general prac-
titioners and other specialists will be essential for some patients
given the impact that PsA has on all aspects of a patient’s life.
3.1.11. Dermatologists should be able to identify possible signs
and symptoms of PsA among their patients with PsO, with
diagnosis to be confirmed by a rheumatologist
Given that the majority of patients with PsA have already been
diagnosed with PsO, [2,4] dermatologists have been described as
‘sentinels’ for the early detection of PsA [24]. In countries such as the
UK, in which the majority of patients with mild PsO are managed in
primary care, annual assessment for PsA by primary care physicians
is recommended in national guidance [27,57]. Both dermatologists
and, as required, primary care physicians, should systematically
screen for wide-ranging clinical manifestations of PsA and refer to
a rheumatologist for imaging tests and a diagnosis [24]. Key cli-
nical signs and symptoms of PsA are broad, often beginning with
osteomuscular pain and tender joints. Further symptoms include
peripheral inflammatory pain; axial inflammatory pain; dactylitis;
and buttock and sciatic pain [58]. This makes a differential diagno-
sis of PsA (as opposed to another musculoskeletal disease) difficult.
Use of validated PsA screening questionnaires, [59–63] with edu-
cational support for dermatologists and primary care physicians as
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.1.12. High-quality patient–clinician education and patient
nderstanding is key to ensuring adherence
The rate of adherence in patients taking biologics for PsA has
een reported to be > 70% in studies of golimumab, adalimumab and
tanercept [64,65]. However, one study reported that treatment
witches occurred in 42% of patients with adalimumab and 47%
f patients with etanercept prescriptions [65]. Patients who  have
reviously used biologics generally have better adherence and per-
istence. Younger age, female gender, higher out-of-pocket costs,
reater disease severity and more comorbidities have all been asso-
iated with lower rates of treatment adherence and persistence in
 study of patients with rheumatoid arthritis, PsO or PsA [64].
Although it is widely acknowledged that adherence is multi-
actorial, patient–clinician interactions play an important role and
he consultation provides a helpful means of engaging patients in
heir own care. Shared decision-making between the patient and
he clinician has been identified as one of the keys to optimising
reatment adherence [66].
However, data show a relatively high rate of discordance (29%)
etween patient and physician global assessment of disease impact
n 460 patients with PsA. In cases of discordance, most patients
85.8%) rated their global assessment higher than did their phy-
ician [67]. These data may  indicate that physicians are missing
ome signs of disease activity or some aspects of the disease that
re especially relevant to the patient. For example, physicians may
e evaluating pathological severity but not fully considering the
mpact of the disease on a patient’s overall well-being. The lat-
er hypothesis is supported by the observation that key drivers
f the discordance were fatigue, lower self-perceived coping and
mpaired social participation [67]. Another study in 565 patients
ith PsA found that fatigue, pain and tender joint count accounted
or much of the difference between physician and patient assess-
ent of disease activity [68]. Discordance between physicians and
atients can be an obstacle to shared decision-making, with neither
arty fully understanding the perspective of the other. Every effort
hould be made to minimise discordance, with the first step being
wareness of key drivers, such as fatigue.
. Discussion
Using a robust modified Delphi consensus process, we propose
2 recommendations on the diagnosis, management, and educa-
ion of PsA that could be used as a practical framework to guide
nd refine multidisciplinary care.
The process of developing these statements brought to light
he complexity and challenges of accurate and consistent assess-
ent, as well as providing multidisciplinary care in PsA across a
ange of European settings. We  acknowledge that defining a rigid
emplate or imposing practices would be counterproductive. Our
im was to set out principles rather than to impose organisational
r administrative structures. The result of this exercise is a set of
exible principles within a practical framework that serve as a call-
o-action to implement, refine and optimise multidisciplinary care
ractices in PsA. In addition, some areas have been identified in
hich evidence is absent or insufficient, with a need for concerted
ata collection. We  acknowledge that the implementation of these
rinciples may  differ according to the variation and limitations of
ifferent healthcare models. Our recommendations can be inter-
reted and applied within local healthcare systems, as outlined in
he suggested implementation strategies relating to Recommenda-
ion 9.PsA is a disease that has multisystemic effects that require a
olistic treatment approach (Fig. 1) [54,69]. Ideally, patient care
hould be regularly reviewed by the necessary range of specia-
ists throughout the patient journey, making collaborative care































Fig. 1. PsA is a multi-domain disease that requires
the usual format of care rather than the exception. Attendance
at a multidisciplinary clinic at pre-specified milestones is one
way of achieving this and multidisciplinary clinics are increasingly
common: in the United States, for example, more than 20 derma-
tology/rheumatology clinics were reported in 2018 [5,12]. In these
integrated clinics, dermatologists and rheumatologists carry out
patient consultations either together or sequentially, and disease
management is typically underpinned by an agreed referral process
and clinical protocol [70,71]. Although integrated clinics have been
associated with high levels of patient satisfaction, [16] shared best
practice could further refine the quality of care provided [71,72].
In particular, staff resourcing may  need to be adapted to improve
scheduling, given that dermatologists typically see an average of
15–20 patients in a half-day, whereas a rheumatologist would see
6–8 patients in the same time period [73]. A possible solution
proposed by the experts involves specialist rheumatology nurses
supporting the patient in managing their PsA and any treatment-
related side effects. This nurse-led approach can ease pressure on
resources and consultation time, permitting the rheumatologist to
focus their consultations on patients with complex needs. There
are, no doubt, improvements in efficiency that can be made; in
one study of 320 patients, a large proportion of dermatological
diagnoses were unrelated to patients’ rheumatological diagnoses,
and these patients, once identified, do not need to be seen during
integrated clinic hours [14]. The panel noted that, owing to the limi-
tations of healthcare resources, many patients are returned to the
care of a single specialism once a particular clinical problem has
been addressed (for example, a new treatment regimen has been
initiated and is found to be effective). This model is particularly use-
ful in reviewing the management of problematic patients: in one
study, the majority of patients either received a revised diagnosis
or a change in treatment [15]. However, as shown in primary care,
[74] continuity of care is linked to patient satisfaction.
The experts recommended the local development of evidence-





disciplinary specialist care. PsA, psoriatic arthritis.
riteria for referral, monitoring of disease activity, evaluation and
anagement of treatment-associated side effects, and treatment
witching. These could form the basis of training of healthcare
rofessionals who  are involved in local PsA care, and be used to
hare knowledge between dermatologists, rheumatologists, psy-
hologists, physiotherapists, gastroenterologists, specialist nurses
nd primary care professionals, ensuring that each role is defi-
ed in line with local needs and with input from each relevant
pecialist.
The consensus process highlighted that a vital part of any mul-
idisciplinary set-up should be data collection, to evaluate patients’
hort- and long-term clinical outcomes and QoL. Assessment of
ost-effectiveness and healthcare resource use will also be impor-
ant. Eventually, it is hoped that data collection will provide insights
bout the impact of early treatment on disease progression. Better
nderstanding of the pathophysiological basis of PsA, and of the
ransition from PsO to PsA, may  help to identify patients with PsO
ho have the highest risk of developing PsA. Having a system in
lace that supports early treatment of PsA may  therefore help us
o identify preventive strategies [75].
The process outlined in this paper had a number of strengths and
imitations. An obvious strength is the extensive clinical experience
nd practical insights provided by our expert panel. However, a
roader expert panel may  be considered in future updates to the
tatements. Literature searches were limited to papers published in
nglish. Statements were developed without input from patients,
lthough the literature search did include studies that addressed
he patient perspective. We  acknowledge that this is not an ade-
uate substitute for real patient input at the consensus-seeking
tage.
These statements are based on a narrative review of the lite-
ature, as well as sharing of extensive clinical experience among
xperts in the management of patients with PsA. Once the majority
f patients with PsA are receiving regular multidisciplinary care,
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with new directions for research into the very early stages of this
debilitating disease.
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